SEOUL, South Korea, Dec. 29, 2022 /PRNewswire/ -- VectorBuilder is the world's largest supplier of customized vectors for viral and non-viral gene delivery, operating as a multinational corporation headquartered in Chicago, USA with offices in North America, Europe, China, Japan, Korea, Australia and Israel. Currently, more than 80,000 custom vectors are produced annually for numerous researchers around the world. VectorBuilder has GMP facilities for gene delivery systems, and supplies gene therapy products and delivery systems for thousands of institutions around the world and more than 50,000 customers, including all the leading pharmaceutical companies and major universities. We are supplying gene therapy products and delivery systems.
VectorBuilder Biotechnology has secured investor backing for its push to support gene delivery, raising a 410 million Chinese yuan ($57 million) series C financing round to upgrade and expand its R&D and manufacturing capabilities.
VectorBuilder Biotechnology (Guangzhou) Co., a top gene delivery startup, recently announced the completion of its Series C round with CNY410 million, co-led by Legend Capital. The proceeds will facilitate VectorBuilder in continuously promoting the upgrading and capacity expansion of the gene delivery R&D and production technology platform, further accelerate the global business presence, and boost the R&D of life sciences and genetic medicines.